Frazier Life Sciences Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Frazier Life Sciences Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$259M	Hold	9,874,511	–	–	5.64%	5
2026 Q1	$233M	Hold	9,874,511	–	–	5.99%	5
2025 Q4	$287M	Hold	9,874,511	–	–	7.7%	3
2025 Q3	$186M	Hold	9,874,511	–	–	5.58%	5
2025 Q2	$138M	Buy	9,874,511 +1,089,227	+12%	+$15.3M	5.54%	5
2025 Q1	$137M	Hold	8,785,284	–	–	6.28%	4
2024 Q4	$122M	Hold	8,785,284	–	–	5.08%	5
2024 Q3	$81.7M	Hold	8,785,284	–	–	3.27%	11
2024 Q2	$81.7M	Hold	8,785,284	–	–	3.82%	8
2024 Q1	$87.1M	Buy	8,785,284 +21,052	+0.2%	+$157K	3.67%	9
2023 Q4	$28.3M	Buy	8,764,232 +80,000	+0.9%	+$217K	1.51%	19
2023 Q3	$46.1M	Hold	8,684,232	–	–	3.06%	11
2023 Q2	$82.8M	Hold	8,684,232	–	–	4.94%	7
2023 Q1	$95.5M	Hold	8,684,232	–	–	6.92%	4
2022 Q4	$129M	Hold	8,684,232	–	–	7.99%	3
2022 Q3	$166M	Buy	8,684,232 +250,000	+3%	+$5.66M	12.78%	2
2022 Q2	$180M	Hold	8,434,232	–	–	16.96%	1
2022 Q1	$162M	Buy	+8,434,232	New	+$143M	13.84%	1

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Frazier Life Sciences Management's ARQT Position: Q2 2026 in Review

Frazier Life Sciences Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 9,874,511 shares worth $259M. The position accounts for 5.64% of the portfolio, ranked #5.

Frazier Life Sciences Management first reported a position in ARQT in Q1 2022 and has held it in 18 quarters since. The position peaked at $287M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Frazier Life Sciences Management held 9,874,511 shares of Arcutis Biotherapeutics worth $259M as of Q2 2026.
Frazier Life Sciences Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 5.64% of Frazier Life Sciences Management's portfolio in Q2 2026, its #5 holding.
Frazier Life Sciences Management first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
Frazier Life Sciences Management's Arcutis Biotherapeutics position peaked at $287M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.